Colorectal Cancer

Zanzalintinib Plus Atezolizumab Improves Survival in Refractory MSS Metastatic Colorectal Cancer

Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit from immunotherapy. In the phase...

Latest Post

SAKK 41/13 Trial: Adjuvant Aspirin Shows Promise in PIK3CA-Mutant Colon Cancer

First randomized trial shows aspirin 100mg daily improves disease-free survival in PIK3CA-mutant colon cancer patients.

Distinct Genomic Mutation Patterns Identified in Early-Onset Colorectal Cancer: International Multi-Cohort Analysis

EOCRC exhibited significantly higher TMB compared with LOCRC in hypermutated tumors, with distinct gene mutation...

Colorectal Cancer Screening Uptake Increases Following USPSTF Guidelines for Ages 45-49

CRC screening in ages 45-49 jumped from 20.8% to 33.7% post-USPSTF guidelines, but gains limited...

The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice

MT-sDNA screening showed 0.2% CRC detection rate and 73% false-positive rate, raising questions about effectiveness...

GI Cancer Insight Center

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest

Colorectal Cancer

Zanzalintinib Plus Atezolizumab Improves Survival in Refractory MSS Metastatic Colorectal Cancer

Latest Post

SAKK 41/13 Trial: Adjuvant Aspirin Shows Promise in PIK3CA-Mutant Colon Cancer

Distinct Genomic Mutation Patterns Identified in Early-Onset Colorectal Cancer: International Multi-Cohort Analysis

Colorectal Cancer Screening Uptake Increases Following USPSTF Guidelines for Ages 45-49

The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice

GI Cancer Insight Center

Bile Duct Cancer (Cholangiocarcinoma)

Upper GI/Gastroesophageal Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gallbladder Cancer